The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Cell Therapy Manufacturing Market (4th edition) by Type of Cell Manufactured (Immune Cells, Stem Cells and Others), Source of Cell (Autologous and Allogeneic), Scale of Operation (Preclinical, Clinical and Commercial), Purpose of Manufacturing (In-house and Contract) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America and MENA) - Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    May 2021

  • Pages
    550

  • View Count
    20012

Example Insights

Cell-Therapy-Manufacturing-Market-Context Cell-Therapy-Manufacturing-Market-Market-Landscape Cell-Therapy-Manufacturing-Market-Distribution-by-Company-Size-and-HQ Cell-Therapy-Manufacturing-Market-Geographical-Distribution-by-Location-of-Manufacturing-Facility
Cell-Therapy-Manufacturing-Market-Partnerships-and-Collaborations Cell-Therapy-Manufacturing-Market-Recent-Expansions Cell-Therapy-Manufacturing-Market-Big-Pharma-Initiatives Cell-Therapy-Manufacturing-Market-List-of-Automated-and-Closed-Cell-Therapy-Processing-Systems
Cell-Therapy-Manufacturing-Market-Capacity-Analysis Cell-Therapy-Manufacturing-Market-Distribution-by-Source-of-Cells Cell-Therapy-Manufacturing-Market-Future-Forecast  

 

Overview

The cost of cell-based therapies depends on various factors, such as duration of manufacturing, vector-based cell transfection and extent of gene modification. Price of such products has been observed to vary between USD 2,000 (for cartilage implants) to USD 50,000-60,000 (for cell and gene therapies).

-- CEO, a small-sized cell therapies manufacturer

Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry. In fact, in February 2021, the USFDA approved Breyanzi®, a CAR-T cell-based therapy, developed by Bristol Myers Squibb, which is designed to treat relapsed or refractory large B-cell lymphoma. According to a recent report (published by The Alliance for Regenerative Medicine), over 1,200 clinical trials, focused on the evaluation of cell therapies, gene therapies and tissue-based therapies, are currently being conducted by over 1,000 organizations (including academic institutions), worldwide. Further growth of the market is primarily hindered by the limited availability of expertise, lack of specialized infrastructure to produce cell therapies, and several product development and manufacturing related challenges. With a sufficient body of evidence, validating the clinical benefits / therapeutic potential of this complex class of biologic drugs, the focus of stakeholders in this industry segment has now shifted to optimizing the cell therapy manufacturing process. Moreover, as more big pharma players enter this field of research, there is likely to be a substantial rise in the cell therapy manufacturing demand, as the proprietary product candidates of these large companies mature and need to be mass produced. In order to address the concerns related to manufacturing, several cell therapy developers (including the larger companies) have turned to contract manufacturing organizations (CMOs).

The cell therapy manufacturing service landscape features a mix of industry players (including well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes. It is worth highlighting that innovator companies that have the required capabilities and facilities to produce cell therapies for in-house requirements, also offer contract services (primarily to ensure the optimum use of their resources and open up additional revenue generation opportunities). Further, in order to make cell therapies more affordable, several stakeholders are integrating various degrees of automation to cut down on labor costs and also improve process scalability. This specialty services industry has witnessed significant partnership activity over the past few years, with several companies being acquired by the larger firms, in efforts to grow and consolidate their capabilities in this space. As stakeholders strive to mitigate existing challenges and focus on innovation to improve the cell production process, we believe that the market will witness significant growth in mid-long term.

Scope of the Report

The “Cell Therapy Manufacturing Market (4th Edition) by Type of Cell Manufactured (Immune Cells, Stem Cells and Others ), Source of Cell (Autologous and Allogeneic), Scale of Operation (Preclinical, Clinical and Commercial), Purpose of Manufacturing (In-house and Contract) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America and MENA) - Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing, along with information on both contract manufacturers, as well as developers having in-house production capabilities, offering in-depth analyses of the various business entities engaged in this domain, across key global regions. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of players engaged in the manufacturing of cell-based therapies, along with information on type of cell manufactured (including immune cells (including T cells, dendritic cells, NK cells), stem cells (including adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), source of cell (autologous and allogeneic), scale of operation (preclinical, clinical and commercial), purpose of production (fulfilling in-house requirements and contract services), manufacturing capabilities / services offered (including R&D, cell culture development, quality testing, packaging, cell banking, supply chain management services, and regulatory services), as well as location of headquarters and their respective manufacturing facilities. 
  • An analysis of the various expansion initiatives undertaken by service providers engaged in this domain in order to augment their respective cell therapy manufacturing capabilities, during the period 2016-2021, based on several relevant parameters, such as year of expansion, type of cell manufactured, scale of operation, purpose of expansion (facility expansion and new facility), location of expanded manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken).
  • An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established during the period 2016-2021, based on several relevant parameters, such as the year of agreement, type of partnership model adopted, type of cell and scale of operation.
  • A review of the various cell therapy manufacturing initiatives undertaken by big pharma players engaged in this domain, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of cell manufactured.
  • Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of patients), based on type of cell therapy and key geographical regions. 
  • An estimate of the overall, installed capacity for the manufacturing of cell-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific).
  • An in-depth analysis of cell therapy manufacturers using three versatile representations, namely [A] a three dimensional grid analysis, presenting the distribution of companies on the basis of type of cell manufactured, scale of operation and purpose of production, [B] a logo landscape, based on the type of cell manufactured, geographical location of manufacturer (North America, Europe and Asia Pacific), and type and size of organization (non-industry players, and small, mid-sized and large companies), and [C] a schematic world map representation, highlighting the geographical location of cell therapy manufacturing facilities of both industry and non-industry stakeholders.
  • A detailed analysis of various factors that are likely to influence the price of cell-based therapies, featuring different models / approaches adopted by manufacturers while determining the price of their proprietary offerings.
  • An elaborate discussion on the role of automation technologies in improving the current manufacturing methods, along with a comparative (qualitive) analysis of cost differences between manual and automated processes.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A discussion on cell therapy manufacturing regulations across various geographies, including North America (focusing on the US), Europe and Asia (focusing on Japan and China), featuring an analysis of the diverse certifications / accreditations awarded to manufacturing facilities by important regulatory bodies across the globe.
  • Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services for cell-based therapies; each profile includes an overview of the company / organization, information on its manufacturing facilities, service portfolio, recent partnerships and an informed future outlook. 
  • A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry’s evolution, under an elaborate SWOT framework, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall market dynamics.
  • Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly / indirectly involved in the development and / or manufacturing of cell-based therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the cell therapy manufacturing market. Based on parameters, such as number of ongoing / planned clinical studies, cell therapy manufacturing costs, target patient population, and anticipated adoption of such products, we have provided informed estimates on the evolution of the market in the short to mid-term and mid to long term, for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of cell therapy (T cell therapies,dendritic and tumor cell therapies, NK cell therapies, stem cell therapies and others), [B] source of cell (autologous and allogeneic), [C] scale of operation (clinical and commercial), [D] purpose of manufacturing (in-house and contract), and [E] key geographical regions (North America, Europe, Asia Pacific, Latin America and MENA). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Gilles Devillers (General Manager, Bio Elpida)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Arik Hasson (Executive VP Research and Development, Kadimastem)
  • Fiona Bellot (Business Development Manager, Roslin CT)
  • David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR) 
  • Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy) 
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, Yposkesi)Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Gerard MJ Bos (Chief Executive Officer, CiMaas)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What is the current, annual, global demand for cell-based therapies? How is the demand for such products likely to evolve over the next decade?
  • What is the current, installed contract manufacturing capacity for cell therapies?
  • What are the key parameters governing the price of cell therapies?
  • What are the key recent developments (such as partnerships and expansions) in this industry? 
  • What kind of partnership models are commonly adopted by stakeholders engaged in this domain? 
  • What are the different initiatives undertaken by big pharma players for the manufacturing of cell therapies in the recent past?
  • What different types of automated technology platforms available for the development and manufacturing of cell therapies? 
  • Who are the key players (industry / non-industry) engaged in the manufacturing of cell-based therapies across the world?
  • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to cell therapies? 
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outline

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the cell-based therapy manufacturing market and its likely evolution in the short to mid-term, and long term.

Chapter 3 provides a general introduction to cell-based therapies and ATMPs. It further includes a detailed discussion on the manufacturing process of cell-based therapies, and associated challenges, along with highlighting the applications of currently approved products. Additionally, it highlights information on the different manufacturing models (centralized and decentralized) that are being used for the production of cell-based therapies, as well as their associated advantages and disadvantages. Furthermore, it features details related to the scalability of cell-based therapies. The chapter also includes a brief overview of the role of automation and the need for effective supply chain management for cell-based therapies.

Chapter 4 features a detailed list of all the industry, as well as non-industry players that are actively involved in the manufacturing of cell-based therapies. It provides information on the type of cell manufactured (including immune cells (including T cells, dendritic cells, NK cells), stem cells (including adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), source of cell (autologous and allogeneic), scale of operation (preclinical, clinical and commercial), purpose of production (fulfilling in-house requirements and contract services), manufacturing capabilities / services offered (including R&D, cell culture development, quality testing, packaging, cell banking, supply chain management services, and regulatory services), as well as location of headquarters and their respective manufacturing facilities.

Chapter 5 features a detailed discussion on the regulatory landscape related to cell therapies across various geographies, such as the US, Europe, Japan and China. Further, it presents an analysis of the manufacturing facilities on basis of the certifications awarded (for manufacturing cell-based therapies) to individual sites by various regulatory bodies across the globe. 
 
Chapter 6 describes the strategies that are likely to be adopted to accelerate the translation of cell-based therapies from laboratory to clinics. It provides details on roadmaps published by different organizations located across various geographies, specifically in the US. 

Chapter 7 discusses the role of automation technologies in optimization of current manufacturing practices with the use of closed and single use systems. Further, it features a roadmap that provides information on the steps to develop automation devices, supported by two case studies. It also presents a qualitive analysis on the cost incurred while manufacturing cell-based therapies using manual versus automated manufacturing approaches. In addition, it features a list of organizations that offer automated technologies for manufacturing operations or provide services to therapy developers to automate their production processes.  

Chapter 8 features detailed profiles of industry players that offer contract manufacturing services for cell therapies at the clinical and / or commercial scales. Each profile provides a brief overview of the company, details on its manufacturing capabilities and facilities, recent partnerships and an informed future outlook. 

Chapter 9 features profiles of non-industry players that offer contract manufacturing services for cell therapies. Each profile provides a brief overview of the organization, and details on its service portfolio and manufacturing facilities. 

Chapter 10 discusses the role of non-profit organizations in this domain. It provides a list of organizations that are actively involved in the development and production of cell-based therapies, across different global regions. Further, it includes profiles of organizations that provide financial and / or technological support to cell therapy manufacturers and developers. Additionally, the chapter provides information on various international / national societies that help in disseminating knowledge about the advancement of these therapies to the general community.  

Chapter 11 features an analysis of the various partnerships and collaborations that have been inked amongst players engaged in this domain, between 2016-2021 (till February). It includes a brief description on the various types of partnership models that are employed by stakeholders in this market, and an analysis on the trend of partnerships. It also includes analyses based on year of agreement, type of partnership, scale of operation, type of cell manufactured and most active players. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals. Further, the chapter features an analysis of the various acquisitions that have taken place in this domain, highlighting geographical activity. The analysis also features an ownership change matrix, providing insights on the involvement of private and public sector entities in this domain.

Chapter 12 presents detailed analysis on the expansions that have taken place in the cell therapy manufacturing industry, since 2016. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain. The expansion instances were analyzed based on various parameters, including year of expansion, type of cell manufactured, scale of operation, purpose of expansion (facility expansion and new facility), location of expanded manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken). 

Chapter 13 provides a detailed analysis of the various cell therapy manufacturing initiatives undertaken by big pharma players engaged in this domain, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of cell manufactured.

Chapter 14 features a comprehensive analysis of the overall installed capacity of cell-based therapy manufacturers. The analysis is based on meticulous data collection of reported capacities, via both secondary and primary research, of various small, mid-sized and large companies, and non-industry players distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the cell-based therapy production capabilities of organizations across different types of organization (industry and non-industry), scale of operation (clinical and commercial), geographies (North America, Europe and Asia Pacific) and company size (small, mid-sized and large organizations).

Chapter 15 features a detailed analysis of the annual demand for cell therapies (in terms of number of patients), considering various relevant parameters, such as target patient population, dosing frequency and dose strength of the approved cell therapies, as well as those therapies that are currently being evaluated in clinical trials. The demand analysis has been segmented across different types of cell therapies (including CAR-T cells, TCR cells, TIL cells, NK cells, dendritic cells, tumor cells and stem cells), scale of operation (clinical and commercial) and regions (North America, Europe and Asia Pacific).

Chapter 16 highlights our views on various factors, including manufacturing costs, that may be taken into consideration while pricing cell-based therapies. It features discussions on different pricing models / approaches adopted by manufacturers to decide the price of its proprietary products.

Chapter 17 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by cell therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 18 presents an elaborate market forecast analysis, highlighting the future potential of the market till the year 2030. The chapter presents a detailed market segmentation on the basis of [A] type of cell therapy (T cell therapies, dendritic and tumor cell therapies, NK cell therapies, stem cell therapies and others), [B] source of cell (autologous and allogeneic), [C] scale of operation (clinical and commercial), [D] purpose of manufacturing (in-house and contract), and [E] key geographical regions (North America, Europe, Asia Pacific and Latin America and MENA). 

Chapter 19 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of cell-based therapy manufacturers on the basis of type of cell manufactured, scale of operation and purpose of production (fulfilling in-house requirement / contract service provider). In addition, it consists of two logo landscapes, representing the distribution of cell-based therapy manufacturers based on the type of cell manufactured (immune cells and stem cells), geographical regions (North America, Europe and Asia Pacific) and the type / size of organization (non-industry, small, mid-sized and large companies). The chapter also comprises of two schematic world map representations to highlight the locations of various cell-based therapy manufacturing facilities across different continents. 

Chapter 20 provides a discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall cell therapy manufacturing industry.

Chapter 21 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the cell therapy manufacturing market. 

Chapter 22 presents insights from the survey conducted for this study. We invited over 100 stakeholders involved in the development and / or manufacturing of different types of cell therapies. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 23 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics), Gilles Devillers (General Manager, Bio Elpida), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Arik Hasson (Executive VP Research and Development, Kadimastem), Fiona Bellot (Business Development Manager, Roslin CT), David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, Yposkesi), Tim Oldham (Chief Executive Officer, Cell Therapies) and Gerard MJ Bos (Chief Executive Officer, CiMaas).

Chapter 24 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 25 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Introduction to Cell-based Therapies
3.2.1. Comparison of Cell-based Therapies and Other Biotechnology Products
3.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
3.2.3. Current Market Landscape of ATMPs

3.3. Overview of Cell Therapy Manufacturing
3.4. Cell Therapy Manufacturing Models
3.4.1. Centralized Manufacturing
3.4.2. Decentralized Manufacturing
3.5. Scalability of Cell Therapy Manufacturing Processes
3.5.1. Scale-up
3.5.2. Scale-out

3.6. Types of Cell Therapy Manufacturers
3.7. Key Challenges Associated with Manufacturing of Cell Therapies
3.8. Factors Influencing Cell Therapy Manufacturing
3.9. Automation of Cell Therapy Manufacturing Processes
3.10. Cell Therapy Manufacturing Supply Chain
3.11. Future Perspectives

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Cell Therapy Manufacturing (Industry Players): Overall Market Landscape
4.2.1. Analysis by Company Size
4.2.2. Analysis by Year of Establishment
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Manufacturing Facility
4.2.5. Analysis by Type of Manufacturer
4.2.6. Analysis by Type of Cell Manufactured
4.2.7. Analysis by Source of Cells
4.2.8. Analysis by Scale of Operation
4.2.9. Analysis by Manufacturing Capabilities / Services Offered

4.3. Cell Therapy Manufacturing (Non-Industry Players): Overall Market Landscape
4.3.1. Analysis by Location of Headquarters
4.3.2. Analysis by Location of Manufacturing Facility
4.3.3. Analysis by Type of Manufacturer
4.3.4. Analysis by Type of Cell Manufactured
4.3.5. Analysis by Source of Cells
4.3.6. Analysis by Scale of Operation
4.3.7. Analysis by Manufacturing Capabilities / Services Offered

5. REGULATORY LANDSCAPE
5.1. Chapter Overview
5.2. Current Scenario
5.2.1. Regulatory Guidelines in North America
5.2.2. Regulatory Guidelines in Europe
5.2.3. Regulatory Guidelines in Japan
5.2.4. Regulatory Guidelines in China
5.2.5. Conditional Approvals

5.3. Regulatory Accreditations for Cell Therapy Manufacturing
5.3.1. Facilities Approved by Regulators for Cell Therapy Manufacturing
5.4. Summary of Guidelines for Clinical-stage Manufacturing of Cell Therapies
5.5. Existing Challenges Associated with Clinical-stage Manufacturing of Cell Therapies
5.5.1. Variability in Regulatory Guidelines Established across Different Geographies

6. ROADMAPS FOR OVERCOMING CHALLENGES
6.1. Chapter Overview
6.2. Roadmap for the US
6.2.1. Cell Processing
6.2.2. Cell Preservation, Distribution and Handling
6.2.3. Process Automation and Data Analytics
6.2.4. Process Monitoring and Quality Control
6.2.5. Standardization and Regulatory Support
6.2.6. Workforce Development
6.2.7. Supply Chain and Logistics
6.3. Roadmaps for Other Geographies
6.3.1. Europe
6.3.2. Asia Pacific

7. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING
7.1. Chapter Overview
7.2. Automation of Cell Therapy Manufacturing Processes
7.2.1. Closed Systems
7.2.2. Single-use Systems
7.2.3. Modular Systems
7.3. Growth Drivers and Roadblocks
7.4. Case Studies
7.4.1. Roadmap for Developing an Automated Cell Manufacturing / Processing Device
7.4.2. Automating the Cell Therapy Manufacturing Process
7.5. GMP-in-a-Box
7.6. List of Automated and Closed Cell Therapy Processing Systems
7.7. Comparative Analysis of Manual and Automated Processes

8. PROFILES: INDUSTRY PLAYERS
8.1. Chapter Overview
8.2. Service Providers in North America
8.2.1 Cognate BioServices
8.2.1.1. Company Overview
8.2.1.2. Service Portfolio
8.2.1.3. Manufacturing Facilities and Capabilities
8.2.1.4. Partnerships
8.2.1.5. Future Outlook

8.2.2. KBI Biopharma
8.2.2.1. Company Overview
8.2.2.2. Service Portfolio
8.2.2.3. Manufacturing Facilities and Capabilities
8.2.2.4. Partnerships
8.2.2.5. Future Outlook

8.2.3. Waisman Biomanufacturing
8.2.3.1. Company Overview
8.2.3.2. Service Portfolio
8.2.3.3. Manufacturing Facilities and Capabilities
8.2.3.4. Partnerships
8.2.3.5. Future Outlook

8.3. Service Providers in Europe
8.3.1. BioNTech Innovative Manufacturing Services
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.3. Manufacturing Facilities and Capabilities
8.3.1.4. Partnerships
8.3.1.5. Future Outlook

8.3.2. Cell and Gene Therapy Catapult
8.3.2.1. Company Overview
8.3.2.2. Service Portfolio
8.3.2.3. Manufacturing Facilities and Capabilities
8.3.2.4. Partnerships
8.3.2.5. Future Outlook

8.3.3. Lonza
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio
8.3.3.3. Manufacturing Facilities and Capabilities
8.3.3.4. Partnerships
8.3.3.5. Future Outlook

8.3.4. Roslin Cell Therapies
8.3.4.1. Company Overview
8.3.4.2. Service Portfolio
8.3.4.3. Manufacturing Facilities and Capabilities
8.3.4.4. Partnerships
8.3.4.5. Future Outlook

8.4. Service Providers in Asia Pacific
8.4.1. Cell Therapies
8.4.1.1. Company Overview
8.4.1.2. Service Portfolio
8.4.1.3. Manufacturing Facilities and Capabilities
8.4.1.4. Partnerships
8.4.1.5. Future Outlook

8.4.2. FUJIFILM Cellular Dynamics
8.4.2.1. Company Overview
8.4.2.2. Service Portfolio
8.4.2.3. Manufacturing Facilities and Capabilities
8.4.2.4. Partnerships
8.4.2.5. Future Outlook

8.4.3. Minaris Regenerative Medicine
8.4.3.1. Company Overview
8.4.3.2. Service Portfolio
8.4.3.3. Manufacturing Facilities and Capabilities
8.4.3.4. Partnerships
8.4.3.5. Future Outlook

8.4.4. MEDINET
8.4.4.1. Company Overview
8.4.4.2. Service Portfolio
8.4.4.3. Manufacturing Facilities and Capabilities
8.4.4.4. Partnerships
8.4.4.5. Future Outlook

8.4.5. Nikon CeLL Innovation
8.4.5.1. Company Overview
8.4.5.2. Service Portfolio
8.4.5.3. Manufacturing Facilities and Capabilities
8.4.5.4. Partnerships
8.4.5.5. Future Outlook

8.4.6. WuXi AppTec
8.4.6.1. Company Overview
8.4.6.2. Service Portfolio
8.4.6.3. Manufacturing Facilities and Capabilities
8.4.6.4. Partnerships
8.4.6.5. Future Outlook

9. PROFILES: NON-INDUSTRY PLAYERS
9.1. Chapter Overview
9.2. Center for Cell and Gene Therapy, Baylor College of Medicine
9.2.1. Overview
9.2.2. Operating Segments
9.2.3. Service Portfolio
9.2.4. Manufacturing Facilities and Capabilities

9.3. Centre for Cell Manufacturing Ireland, National University of Ireland
9.3.1. Overview
9.3.2. Service Portfolio
9.3.3. Manufacturing Facilities and Capabilities

9.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania
9.4.1. Overview
9.4.2. Service Portfolio
9.4.3. Manufacturing Facilities and Capabilities

9.5. Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
9.5.1. Overview
9.5.2. Service Portfolio
9.5.3. Manufacturing Facilities and Capabilities

9.6. Laboratory for Cell and Gene Medicine, Stanford University
9.6.1. Overview
9.6.2. Service Portfolio
9.6.3. Manufacturing Facilities and Capabilities

9.7. Molecular and Cellular Therapeutics, University of Minnesota
9.7.1. Overview
9.7.2. Service Portfolio
9.7.3. Manufacturing Facilities and Capabilities

9.8. Newcastle Advanced Therapies, Newcastle University
9.8.1. Overview
9.8.2. Service Portfolio
9.8.3. Manufacturing Facilities and Capabilities

9.9. Rayne Cell Therapy Suite, King’s College London
9.9.1. Overview
9.9.2. Manufacturing Facilities and Capabilities

9.10. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
9.10.1. Overview
9.10.2. Manufacturing Facilities and Capabilities

9.11. Sydney Cell and Gene Therapy
9.11.1. Overview
9.11.2. Manufacturing Facilities and Capabilities

10. ROLE OF NON-PROFIT ORGANIZATIONS
10.1. Chapter Overview
10.2. Cell Therapy Manufacturing: Non-Profit Organizations
10.2.1. CellCAN
10.2.2. Cell Therapy Manufacturing Cooperative Research Center
10.2.3. National Cell Manufacturing Consortium (NCMC)
10.2.4. California Institute of Regenerative Medicine (CIRM)
10.3. Cell Therapy Manufacturing: International Societies

11. PARTNERSHIPS
11.1. Chapter Overview
11.2. Partnership Models

11.3. Cell Therapy Manufacturing: List of Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership

11.4. Analysis by Type of Cell
11.5. Analysis by Scale of Operation
11.6. Analysis by Region
11.6.1. Country-wise Distribution
11.6.2. Continent-wise Distribution
11.7. Most Active Players: Analysis by Number of Partnerships

11.8. Cell Therapy Manufacturing: List of Acquisitions
11.8.1. Analysis by Year of Acquisition
11.8.2. Analysis by Year of Acquisition and Type of Cell
11.8.3. Analysis by Region
11.8.3.1. Country-wise Distribution
11.8.3.2. Continent-wise Distribution
11.8.4. Ownership Change Matrix

12. FACILITY EXPANSIONS
12.1. Chapter Overview
12.2. Cell Therapy Manufacturing: List of Expansions
12.2.1. Cumulative Year-wise Distribution
12.2.2. Analysis by Purpose of Expansion
12.2.3. Analysis by Types of Cells
12.2.4. Analysis by Scale of Operation
12.2.5. Analysis by Location of Manufacturing Facility
12.2.6. Analysis by Purpose of Expansion and Region
12.2.7. Most Active Players: Analysis by Number of Expansions
12.2.8. Most Active Players: Analysis by Area of Expansion
12.2.9. Analysis by Region and Area of Expansion

13. BIG PHARMA INITIATIVES
13.1. Chapter Overview
13.2. List of Cell Therapy Manufacturing Focused Initiatives of Big Pharma Players
13.2.1. Analysis by Number of Initiatives
13.2.2. Analysis by Year of Initiative
13.2.3. Analysis by Purpose of Initiative
13.2.4. Analysis by Type of Initiative
13.2.4.1. Analysis by Type of Partnership
13.2.4.2. Analysis by Type of Expansion

13.2.5. Analysis by Scale of Operation
13.2.6. Analysis by Types of Cells
13.2.7. Analysis by Year of Initiative and Company
13.2.8. Analysis by Purpose of Initiative and Company
13.2.9. Analysis by Year and Type of Initiative
13.2.10. Analysis by Region of Expansion and Company
13.2.11. Analysis by Types of Cells and Company

13.3. Competitive Benchmarking of Big Pharmaceutical Players
13.3.1. Harvey Ball Analysis: Big Pharma Investment Summary

14. CAPACITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology (Industry Players)
14.2.1 Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
14.2.1.1. Analysis by Company Size
14.2.1.2. Analysis by Scale of Operation
14.2.1.3. Analysis by Location of Manufacturing Facility
14.2.1.4. Analysis by Company Size and Geography
14.2.1.5. Analysis by Scale of Operation and Geography

14.2.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
14.2.2.1. Analysis by Company Size
14.2.2.2. Analysis by Scale of Operation
14.2.2.3. Analysis by Location of Manufacturing Facility
14.2.2.4. Analysis by Company Size and Geography
14.2.2.5. Analysis by Scale of Operation and Geography

14.3. Key Assumptions and Methodology (Non-Industry Players)
14.3.1. Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
14.3.1.1. Analysis by Scale of Operation
14.3.1.2. Analysis by Location of Manufacturing Facility

14.3.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
14.3.2.1. Analysis by Scale of Operation
14.3.2.2. Analysis by Location of Manufacturing Facility
14.4 Concluding Remarks

15. DEMAND ANALYSIS
15.1 Chapter Overview
15.2 Scope and Methodology
15.3 Global Demand for Cell Therapy Manufacturing
15.4 Global Clinical Demand for Cell Therapy Manufacturing
15.4.1. Analysis by Type of Cell Therapy
15.4.2. Analysis by Geographical Location
15.5. Global Commercial Demand for Cell Therapy Manufacturing
15.5.1. Analysis by Type of Cell Therapy
15.5.2. Analysis by Geographical Location

16. COST PRICE ANALYSIS
16.1. Chapter Overview
16.2. Factors Contributing to the High Price of Cell Therapies
16.3. Pricing Models for Cell Therapies
16.3.1. Based on Associated Costs for T-cell Therapies
16.3.2. Based on Associated Costs for Stem Cell Therapies
16.3.3. Based on Availability of Competing Products
16.3.4. Based on Target Patient Segment
16.3.5. Based on the Opinions of Industry Experts
16.4. Cell Therapy Cost Optimization
16.4.1. Role of Cost of Goods Sold
16.4.2. Role of Automation
16.5. Role of Cell Therapy Contract Manufacturing Organizations
16.6. Reimbursement-related Considerations for Cell Therapies
16.6.1. Case Study: The National Institute for Health and Care Excellence’s (NICE) Appraisal of CAR-T Therapies

17. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
17.1. Chapter Overview
17.2. Assumptions and Key Parameters
17.3. Cell Therapy Manufacturing: Make versus Buy Decision Making
17.3.1. Scenario 1
17.3.2. Scenario 2
17.3.3. Scenario 3
17.3.4. Scenario 4
17.4. Concluding Remarks

18. MARKET SIZING AND OPPORTUNITY ANALYSIS
18.1. Chapter Overview
18.2. Scope of the Forecast
18.3. Input Data and Key Assumptions
18.4. Forecast Methodology
18.5. Global Cell Therapy Manufacturing Market, 2021-2030
18.5.1. Cell Therapy Manufacturing Market, 2021-2030: Distribution by Type of Cell Therapy
18.5.2. Cell Therapy Manufacturing Market, 2021-2030: Distribution by Source of Cells
18.5.3. Cell Therapy Manufacturing Market, 2021-2030: Distribution by Scale of Operation
18.5.4. Cell Therapy Manufacturing Market, 2021-2030: Distribution by Purpose of
 Manufacturing
18.5.5. Cell Therapy Manufacturing Market, 2021-2030: Distribution by Region

18.6. Market Opportunity for Commercial Scale Manufacturing of Cell-based Therapies
18.6.1. Global Commercial Scale Manufacturing Market for T-cell Therapies, 2021-2030
18.6.1.1. Commercial Scale Manufacturing Market for T-cell Therapies, 2021-2030: Distribution by Type of Therapy
18.6.1.2. Commercial Scale Manufacturing Market for T-cell Therapies, 2021-2030: Distribution by Source of Cells
18.6.1.3. Commercial Scale Manufacturing Market for T-cell Therapies, 2021-2030: Distribution by Region

18.6.2. Global Commercial Scale Manufacturing Market for NK Cell Therapies, 2021-2030
18.6.2.1. Commercial Scale Manufacturing Market for NK Cell Therapies, 2021-2030: Distribution by Source of Cells
18.6.2.2. Commercial Scale Manufacturing Market for NK Cell Therapies, 2021-2030: Distribution by Region

18.6.3. Global Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030
18.6.3.1. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030: Distribution by Type of Therapy
18.6.3.2. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030: Distribution by Region

18.6.4. Global Commercial Scale Manufacturing Market for Stem Cell Therapies, 2021-2030
18.6.4.1. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2021-2030: Distribution by Source of Cells
18.6.4.2. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2021-2030: Distribution by Region

18.7. Market Opportunity for Clinical Scale Manufacturing of Cell-based Therapies
18.7.1. Global Clinical Scale Manufacturing Market for T-cell Therapies, 2021-2030
18.7.1.1. Clinical Scale Manufacturing Market for T-cell Therapies, 2021-2030: Distribution by Type of Therapy
18.7.1.2. Clinical Scale Manufacturing Market for T-cell Therapies, 2021-2030: Distribution by Source of Cells
18.7.1.3. Clinical Scale Manufacturing Market for T-cell Therapies, 2021-2030: Distribution by Region

18.7.2. Global Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030
18.7.2.1. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030: Distribution by Type of Therapy
18.7.2.2. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030: Distribution by Source of Cells
18.7.2.3. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030: Distribution by Region

18.7.3. Global Clinical Scale Manufacturing Market for NK Cell Therapies, 2021-2030
18.7.3.1. Clinical Scale Manufacturing Market for NK Cell Therapies, 2021-2030: Distribution by Source of Cells
18.7.3.2. Clinical Scale Manufacturing Market for NK Cell Therapies, 2021-2030: Distribution by Region

18.7.4. Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2021-2030
18.7.4.1. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2021-2030: Distribution by Source of Cells
18.7.4.2. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2021-2030: Distribution by Region

19. KEY INSIGHTS
19.1. Chapter Overview
19.2. Cell Therapy Manufacturing: Grid Analysis
19.3. Cell Therapy Manufacturing: Logo Landscape
19.3.1. Cell Therapy Manufacturing: Logo Landscape, Immune Cells
19.3.2. Cell Therapy Manufacturing: Logo Landscape, Stem Cells
19.4. Cell Therapy Manufacturing: World Map Representation based on Location of Manufacturing Facility
19.4.1. Industry Players
19.4.2. Non-Industry Players

20. SWOT ANALYSIS
20.1. Chapter Overview
20.2. Strengths
20.3. Weaknesses
20.4. Opportunities
20.5. Threats
20.6. Comparison of SWOT Factors

21. CONCLUDING REMARKS
21.1. Chapter Overview

22. SURVEY ANALYSIS
22.1. Chapter Overview
22.2. Distribution by Designation of Respondents
22.3. Distribution by Type of Cell Therapy
22.4. Distribution by Scale of Operation
22.5. Distribution by Source of Cells
22.6. Distribution by Type of Cell Culture System Used
22.7. Distribution by Availability of Fill / Finish Services

23. INTERVIEW TRANSCRIPTS
23.1. Chapter Overview
23.2. Glycostem Therapeutics
23.2.1. Company Overview
23.2.2. Interview Transcript: Troels Jordansen, Chief Executive Officer

23.3. Bio Elpida
23.3.1. Company Overview
23.3.2. Interview Transcript: Gilles Devillers, President

23.4. Gracell Biotechnologies
23.4.1. Company Overview
23.4.2. Interview Transcript: Wei (William) Cao, Chief Executive Officer

23.5. Kadimastem
23.5.1. Company Overview
23.5.2. Interview Transcript: Arik Hasson, Executive VP Research and Development

23.6. RoslinCT
23.6.1. Company Overview
23.6.2. Interview Transcript: Fiona Bellot, Business Development Manager

23.7. University of Minnesota
23.7.1. Company Overview
23.7.2. Interview Transcript: David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine

23.8. Lion TCR
23.8.1. Company Overview
23.8.2. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer

23.9. Center for Commercialization of Cancer Immunotherapy / C3i
23.9.1. Company Overview
23.9.2. Interview Transcript: Arnaud Deladeriere, Manager, Business Development & Operations-cGMP Manufacturing Unit

23.10. Waisman Biomanufacturing
23.10.1. Company Overview
23.10.2. Interview Transcript: Brian Dattilo, Manager of Business Development

23.11. Yposkesi
23.11.1. Company Overview
23.11.2. Interview Transcript: Mathilde Girard, Department Leader, Cell Therapy Innovation and Development

23.12. Cell Therapies
23.12.1. Company Overview
23.12.2. Interview Transcript: Tim Oldham, Chief Executive Officer

23.13. CiMaas
23.13.1. Organization Overview
23.13.2. Interview Transcript: Gerard MJ Bos, Chief Executive Officer

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Classification of Advanced Therapy Medicinal Products
Figure 3.2 Decentralized Manufacturing: Process Model
Figure 3.3 Cell Therapy Manufacturing: Types of Manufacturers
Figure 3.4 Cell Therapies: Challenges and Drivers
Figure 3.5 Cell Therapies: Potency as a Critical Quality Attribute
Figure 3.6 Cell Therapy Manufacturing: Supply Chain Model
Figure 4.1 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size
Figure 4.2 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment
Figure 4.3 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 4.6 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 4.7 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Manufacturer
Figure 4.8 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
Figure 4.9 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Figure 4.10 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Figure 4.11 Cell Therapy Manufacturing (Industry Players): Distribution by Source of Cells
Figure 4.12 Cell Therapy Manufacturing (Industry Players): Distribution by Scale of Operation
Figure 4.13 Cell Therapy Manufacturing (Industry Players): Distribution by Manufacturing Capabilities / Services Offered
Figure 4.14 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Region-wise)
Figure 4.15 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Country-wise)
Figure 4.16 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Region-wise)
Figure 4.17 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Country-wise)
Figure 4.18 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Manufacturer
Figure 4.19 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Cell Manufactured
Figure 4.20 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Immune Cell Manufactured
Figure 4.21 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Stem Cell Manufactured
Figure 4.22 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Source of Cells
Figure 4.23 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Scale of Operation
Figure 4.24 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Manufacturing Capabilities / Services Offered
Figure 5.1 Cell Therapy Manufacturing (Industry Players): Distribution by Regulatory Authorities
Figure 5.2 Cell Therapy Manufacturing (Non-Industry Players): Distribution of Manufacturing Facilities by Regulatory Authorities
Figure 7.1 Key Considerations while Automating Cell Therapy Manufacturing Process
Figure 7.2 Requirements for Implementing Closed Systems in Cell Therapy Manufacturing Processes
Figure 7.3 Functions of Automated and Closed Systems at Each Step of the Cell Therapy Manufacturing Process
Figure 7.4 Advantages and Disadvantages Associated with Single-Use Systems
Figure 7.5 Growth Drivers and Roadblocks Related to the Adoption of Automated and Closed Systems
Figure 7.6 Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
Figure 7.7 Cell Therapy Manufacturing: Comparison of Manual and Automated Processes
Figure 7.8 Cell Therapy Manufacturing: Comparison of Manual and Automated Processes Based on Affiliated Costs
Figure 7.9 Cell Therapy Manufacturing: Comparison of Manual and Automated Processes Based on Annual Cost of Manufacturing per Batch
Figure 8.1 Cognate BioServices: Service Portfolio
Figure 8.2 KBI Biopharma: Service Portfolio
Figure 8.3 Waisman Biomanufacturing: Service Portfolio
Figure 8.4 Waisman Biomanufacturing: Clinical Products Portfolio
Figure 8.5 Waisman Biomanufacturing: Quality Assurance and Control
Figure 8.6 Waisman Biomanufacturing: Manufacturing Suites
Figure 8.7 Waisman Biomanufacturing: Overview of Suite Services
Figure 8.8 BioNTech Innovative Manufacturing Services: Service Portfolio
Figure 8.9 Cell and Gene Therapy Catapult: Services
Figure 8.10 Lonza: Historical Timeline
Figure 8.11 Lonza: Key Business Divisions
Figure 8.12 Lonza Pharma and Biotech: Service Portfolio
Figure 8.13 Lonza: Biological Manufacturing Services
Figure 8.14 Lonza: Cell-based Products
Figure 8.15 Roslin Cell Therapies: Service Portfolio
Figure 8.16 Cell Therapies: Service Portfolio
Figure 8.17 FUJIFILM Cellular Dynamics: Service Portfolio
Figure 8.18 Minaris Regenerative Medicine: Service Portfolio
Figure 8.19 MEDINET: Service Portfolio
Figure 8.20 Nikon CeLL Innovation: Service Portfolio
Figure 8.21 WuXi AppTec: Service Portfolio
Figure 9.1 Center for Cell and Gene Therapy: Operating Segments
Figure 9.2 Center for Cell and Gene Therapy: Service Portfolio
Figure 9.3 Center for Cell Manufacturing Ireland: Service Portfolio
Figure 9.4 Molecular and Cellular Therapeutics: Service Portfolio
Figure 9.5 Newcastle Advanced Therapies: Service Portfolio
Figure 11.1 Partnerships: Cumulative Year-wise Trend, 2016-2021 (Till February)
Figure 11.2 Partnerships: Distribution by Type of Partnership
Figure 11.3 Partnerships: Distribution by Year and Type of Partnership
Figure 11.4 Partnerships: Distribution by Type of Cell
Figure 11.5 Heat Map: Distribution by Year and Type of Cell
Figure 11.6 Partnerships: Distribution by Type of Stem Cell
Figure 11.7 Partnerships: Distribution by Type of T-Cell
Figure 11.8 Partnerships: Distribution by Scale of Operation
Figure 11.9 Partnerships: Distribution by Type of Cell and Scale of Operation
Figure 11.10 Partnerships: Country-wise Distribution
Figure 11.11 Partnerships: Continent-wise Distribution
Figure 11.12 Most Active Players: Distribution by Number of Partnerships
Figure 11.13 Acquisitions: Cumulative Year-wise Trend, 2016-2021 (Till February)
Figure 11.14 Acquisitions: Year-wise Distribution by Type of Cell
Figure 11.15 Acquisitions: Country-wise Distribution
Figure 11.16 Acquisitions: Continent-wise Distribution
Figure 11.17 Acquisitions: Ownership Change Matrix
Figure 12.1 Expansions: Cumulative Year-wise Trend, 2016-2021 (Till February)
Figure 12.2 Expansions: Distribution by Purpose of Expansion
Figure 12.3 Expansions: Distribution by Type of Cell
Figure 12.4 Expansions: Distribution by Purpose of Expansion and Type of Cell
Figure 12.5 Expansions: Distribution by Scale of Operation
Figure 12.6 Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
Figure 12.7 Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 12.8 Expansions: Distribution by Purpose of Expansion and Region
Figure 12.9 Most Active Players: Distribution by Number of Expansions
Figure 12.10 Most Active Players: Distribution by Area of Expansion
Figure 12.11 Expansions: Distribution by Region and Area of Expansion
Figure 13.1 Big Pharma Players: Distribution by Number of Cell Therapy Manufacturing Focused Initiatives
Figure 13.2 Big Pharma Players: Cumulative Distribution by Year of Initiative
Figure 13.3 Big Pharma Players: Distribution by Purpose of Initiative
Figure 13.4 Big Pharma Players: Distribution by Type of Initiative
Figure 13.5 Big Pharma Players: Distribution by Type of Partnership
Figure 13.6 Big Pharma Players: Distribution by Type of Expansion
Figure 13.7 Big Pharma Players: Distribution by Scale of Operation
Figure 13.8 Big Pharma Players: Distribution by Types of Cells
Figure 13.9 Big Pharma Players: Distribution by Year of Initiative and Company
Figure 13.10 Big Pharma Players: Distribution by Purpose of Initiative and Company
Figure 13.11 Big Pharma Players: Distribution by Year and Type of Initiative
Figure 13.12 Big Pharma Players: Distribution by Region of Expansion and Company
Figure 13.13 Big Pharma Players: Distribution by Type of Cell and Company
Figure 13.14 Harvey Ball Analysis: Big Pharma Investment Summary
Figure 14.1 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Range of Installed Capacity
Figure 14.2 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size
Figure 14.3 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation
Figure 14.4 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Location of Manufacturing Facility
Figure 14.5 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size and Location of Manufacturing Facility
Figure 14.6 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 14.7 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Range of Installed Capacity
Figure 14.8 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Company Size
Figure 14.9 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
Figure 14.10 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Location of Manufacturing Facility
Figure 14.11 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Company Size and Location of Manufacturing Facility
Figure 14.12 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 14.13 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Range of Installed Capacity
Figure 14.14 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Scale of Operation
Figure 14.15 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Location of Manufacturing Facility
Figure 14.16 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Non-Industry Players): Distribution by Range of Installed Capacity
Figure 14.17 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Non-Industry Players): Distribution by Scale of Operation
Figure 14.18 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Non-Industry Players): Distribution by Location of Manufacturing Facility
Figure 15.1 Global Demand for Cell Therapies, 2021-2030 (Number of Patients)
Figure 15.2 Global Demand for Cell Therapies, 2021-2030 (Billion Cells)
Figure 15.3 Global Clinical Demand for Cell Therapies, 2021-2030 (Number of Patients)
Figure 15.4 Global Clinical Demand for Cell Therapies, 2021-2030: Distribution by Type of Cell Therapy (Number of Patients)
Figure 15.5 Global Clinical Demand for Cell Therapies, 2021-2030: Distribution by Geographical Location (Number of Patients)
Figure 15.6 Global Commercial Demand for Cell Therapies, 2021-2030 (Number of Patients)
Figure 15.7 Global Commercial Demand for Cell Therapies, 2021-2030: Distribution by Type of Cell Therapy (Number of Patients)
Figure 15.8 Global Commercial Demand for Cell Therapies, 2021-2030: Distribution by Geographical Location (Number of Patients)
Figure 16.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 17.1 Make versus Buy Decision Making Framework
Figure 17.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 18.1 Global Cell Therapy Manufacturing Market, 2021-2030 (USD Million)
Figure 18.2 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2021-2030 (USD Million)
Figure 18.3 Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2021-2030 (USD Million)
Figure 18.4 Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 18.5 Cell Therapy Manufacturing Market: Distribution by Purpose of Manufacturing, 2021-2030 (USD Million)
Figure 18.6 Cell Therapy Manufacturing Market: Distribution by Region, 2021-2030 (USD Million)
Figure 18.7 Global Commercial Scale Manufacturing Market for T-cell Therapies, 2021-2030 (USD Million)
Figure 18.8 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution by Type of Therapy, 2021-2030 (USD Million)
Figure 18.9 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
Figure 18.10 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution by Region, 2021-2030 (USD Million)
Figure 18.11 Global Commercial Scale Manufacturing Market for NK Cell Therapies, 2021-2030 (USD Million)
Figure 18.12 Commercial Scale Manufacturing Market for NK Cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
Figure 18.13 Commercial Scale Manufacturing Market for NK Cell Therapies: Distribution by Region, 2021-2030 (USD Million)
Figure 18.14 Global Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030 (USD Million)
Figure 18.15 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies: Distribution by Type of Therapy, 2021-2030 (USD Million)
Figure 18.16 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies: Distribution by Region, 2021-2030 (USD Million)
Figure 18.17 Global Commercial Scale Manufacturing Market for Stem Cell Therapies, 2021-2030 (USD Million)
Figure 18.18 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
Figure 18.19 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distribution by Region, 2021-2030 (USD Million)
Figure 18.20 Global Clinical Scale Manufacturing Market for T-cell Therapies, 2021-2030 (USD Million)
Figure 18.21 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution by Type of Therapy, 2021-2030 (USD Million)
Figure 18.22 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
Figure 18.23 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution by Region, 2021-2030 (USD Million)
Figure 18.24 Global Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2021-2030 (USD Million)
Figure 18.25 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies: Distribution by Type of Therapy, 2021-2030 (USD Million)
Figure 18.26 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
Figure 18.27 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies: Distribution by Region, 2021-2030 (USD Million)
Figure 18.28 Global Clinical Scale Manufacturing Market for NK Cell Therapies, 2021-2030 (USD Million)
Figure 18.29 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
Figure 18.30 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Region, 2021-2030 (USD Million)
Figure 18.31 Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2021-2030 (USD Million)
Figure 18.32 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, 2021-2030 (USD Million)
Figure 18.33 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Region, 2021-2030 (USD Million)
Figure 19.1 Cell Therapy Manufacturing: Grid Analysis by Purpose of Production, Scale of Operation and Types of Cells
Figure 19.2 Cell Therapy Manufacturing: Logo Landscape, Immune Cells
Figure 19.3 Cell Therapy Manufacturing: Logo Landscape, Stem Cells
Figure 19.4 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facility
Figure 19.5 Cell Therapy Manufacturers (Non-Industry Players): Distribution by Location of Manufacturing Facility
Figure 20.1 Cell Therapy Manufacturing: SWOT Analysis
Figure 20.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 21.1 Concluding Remarks: Summary of the Current Market Landscape (Industry Players)
Figure 21.2 Concluding Remarks: Summary of the Current Market Landscape (Non-Industry Players)
Figure 21.3 Concluding Remarks: Summary of Partnerships
Figure 21.4 Concluding Remarks: Summary of Facility Expansions
Figure 21.5 Concluding Remarks: Summary of Big Pharma Initiatives
Figure 21.6 Concluding Remarks: Summary of Capacity Analysis
Figure 21.7 Concluding Remarks: Summary of Demand Analysis
Figure 21.8 Concluding Remarks: Market Sizing and Opportunity Analysis
Figure 22.1 Survey Insights: Distribution of Respondents by Type of Organization
Figure 22.2 Survey Insights: Distribution of Respondents by Location of Manufacturing Facility
Figure 22.3 Survey Insights: Distribution of Respondents by Designation and Seniority
Figure 22.4 Survey Insights: Distribution by Type of Cell Therapy
Figure 22.5 Survey Insights: Distribution by Scale of Operation
Figure 22.6 Survey Insights: Distribution by Source of Cells
Figure 22.7 Survey Insights: Distribution by Type of Cell Culture System Used
Figure 22.8 Survey Insights: Distribution by Availability of Fill / Finish Services

List Of Tables

Table 3.1 Applications of Cell-based Therapies
Table 3.2 Key Differences between Cell Therapy and Biotechnology Products
Table 3.3 Cell-based Therapies: Commercialized Products
Table 3.4 Assessment of Key Cell Therapy Manufacturing Steps
Table 3.5 Advantages and Disadvantages Associated with Centralized and Decentralized Manufacturing Models
Table 4.1 Cell Therapy Manufacturing: List of Industry Players
Table 4.2 Cell Therapy Manufacturing (Industry Players): Information on Type of Manufacturer
Table 4.3 Cell Therapy Manufacturing (Industry Players): Information on Type of Cell Manufactured
Table 4.4 Cell Therapy Manufacturing (Industry Players): Information on Source of Cells and Type of Cell Culture System Used
Table 4.5 Cell Therapy Manufacturing (Industry Players): Information on Scale of Operation
Table 4.6 Cell Therapy Manufacturing (Industry Players): Information on Manufacturing Capabilities / Services Offered
Table 4.7 Cell Therapy Manufacturing: List of Non-Industry Players
Table 4.8 Cell Therapy Manufacturing (Non-Industry Players): Information on Type of Manufacturer
Table 4.9 Cell Therapy Manufacturing (Non-Industry Players): Information on Type of Cell Manufactured
Table 4.10 Cell Therapy Manufacturing (Non-Industry Players): Information on Source of Cells and Type of Cell Culture System Used
Table 4.11 Cell Therapy Manufacturing (Non-Industry Players): Information on Scale of Operation
Table 4.12 Cell Therapy Manufacturing (Non-Industry Players): Information on Manufacturing Capabilities / Services Offered
Table 5.1 Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
Table 5.2 Cell Therapy Manufacturing (Non-Industry Players): Regulatory Authorities
Table 5.3 Cell Therapy: Regulatory Considerations
Table 6.1 Cell Therapy Manufacturing: Roadmap for the US
Table 6.2 Cell Processing: Challenges and Strategies
Table 6.3 Cell Preservation, Distribution and Handling: Challenges and Strategies
Table 6.4 Process Monitoring and Quality Control: Challenges and Strategies
Table 6.5 Standardization and Regulatory Support: Challenges and Strategies
Table 6.6 Workforce Development: Challenges and Strategies
Table 6.7 Supply Chain and Logistics: Challenges and Strategies
Table 6.8 Cell Therapy Manufacturing: Roadmap for the Asia Pacific Economic Cooperation (APEC)
Table 7.1 Cell Therapy Manufacturing: List of Automated and Closed Cell Therapy Processing Systems
Table 7.2 Cell Therapy Manufacturing: Observed Changes in Scale-up Scenario while Switching from Manual to Automated Operations
Table 8.1 Cognate BioServices: Company Overview
Table 8.2 Cognate BioServices: Overview of Manufacturing Capabilities
Table 8.3 Cognate BioServices: Partnerships
Table 8.4 Cognate BioServices: Future Outlook
Table 8.5 KBI Biopharma: Company Overview
Table 8.6 KBI Biopharma: Overview of Manufacturing Capabilities
Table 8.7 KBI Biopharma: Partnerships
Table 8.8 KBI Biopharma: Future Outlook
Table 8.9 Waisman Biomanufacturing: Company Overview
Table 8.10 Waisman Biomanufacturing: Overview of Manufacturing Capabilities
Table 8.11 Waisman Biomanufacturing: Partnerships
Table 8.12 Waisman Biomanufacturing: Future Outlook
Table 8.13 BioNTech Innovative Manufacturing Services: Company Overview
Table 8.14 BioNTech Innovative Manufacturing Services: Overview of Manufacturing Capabilities
Table 8.15 BioNTech Innovative Manufacturing Services: Partnerships
Table 8.16 BioNTech Innovative Manufacturing Services: Future Outlook
Table 8.17 Cell and Gene Therapy Catapult: Company Overview
Table 8.18 Cell and Gene Therapy Catapult: Overview of Manufacturing Capabilities
Table 8.19 Cell and Gene Therapy Catapult: Partnerships
Table 8.20 Cell and Gene Therapy Catapult: Future Outlook
Table 8.21 Lonza: Company Overview
Table 8.22 Lonza: Global Manufacturing Sites
Table 8.23 Lonza: Overview of Manufacturing Capabilities
Table 8.24 Lonza: Partnerships
Table 8.25 Lonza: Future Outlook
Table 8.26 Roslin Cell Therapies: Company Overview
Table 8.27 Roslin Cell Therapies: Overview of Manufacturing Capabilities
Table 8.28 Roslin Cell Therapies: Partnerships
Table 8.29 Roslin Cell Therapies: Future Outlook
Table 8.30 Cell Therapies: Company Overview
Table 8.31 Cell Therapies: Overview of Manufacturing Capabilities
Table 8.32 Cell Therapies: Partnerships
Table 8.33 Cell Therapies: Future Outlook
Table 8.34 FUJIFILM Cellular Dynamics: Company Overview
Table 8.35 FUJIFILM Cellular Dynamics: Overview of Manufacturing Capabilities
Table 8.36 FUJIFILM Cellular Dynamics: Partnerships
Table 8.37 FUJIFILM Cellular Dynamics: Future Outlook
Table 8.38 Minaris Regenerative Medicine: Company Overview
Table 8.39 Minaris Regenerative Medicine: Overview of Manufacturing Capabilities
Table 8.40 Minaris Regenerative Medicine: Partnerships
Table 8.41 Minaris Regenerative Medicine: Future Outlook
Table 8.42 MEDINET: Company Overview
Table 8.43 MEDINET: Overview of Manufacturing Capabilities
Table 8.44 MEDINET: Partnerships
Table 8.45 Nikon CeLL Innovation: Company Overview
Table 8.46 Nikon CeLL Innovation: Overview of Manufacturing Capabilities
Table 8.47 Nikon CeLL Innovation: Partnerships
Table 8.48 Nikon CeLL Innovation: Future Outlook
Table 8.49 WuXi AppTec: Company Overview
Table 8.50 WuXi AppTec: Overview of Manufacturing Capabilities
Table 8.51 WuXi AppTec: Partnerships
Table 8.52 WuXi AppTec: Future Outlook
Table 9.1 Center for Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
Table 9.2 Center for Cell Manufacturing Ireland: Overview of Manufacturing Facilities and Capabilities
Table 9.3 Clinical Cell and Vaccine Production Facility: Overview of Manufacturing Facilities and Capabilities
Table 9.4 Guy’s and St. Thomas GMP Facility: Overview of Manufacturing Facilities and Capabilities
Table 9.5 Laboratory for Cell and Gene Medicine: Overview of Manufacturing Facilities and Capabilities
Table 9.6 Molecular and Cellular Therapeutics: Overview of Manufacturing Facilities and Capabilities
Table 9.7 Newcastle Advanced Therapies: Overview of Manufacturing Facilities and Capabilities
Table 9.8 Rayne Cell Therapy Suite: Overview of Manufacturing Facilities and Capabilities
Table 9.9 Scottish National Blood Transfusion Services: Overview of Manufacturing Services and Capabilities
Table 9.10 Sydney Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
Table 10.1 Cell Therapy Manufacturing: List of Non-Profit Organizations
Table 10.2 CellCAN: Overview
Table 10.3 Cell Therapy Manufacturing Cooperative Research Center: Overview
Table 10.4 National Cell Manufacturing Consortium: Overview
Table 10.5 California’s Institute of Regenerative Medicine: Overview
Table 11.1 Cell Therapy Manufacturing: List of Partnerships
Table 11.2 Partnerships: Information on Types of Cells
Table 11.3 Partnerships: Information on Subtypes of Cells
Table 11.4 Partnerships: Information on Scales of Manufacturing
Table 11.5 Cell Therapy Manufacturing: List of Acquisitions
Table 12.1 Cell Therapy Manufacturing: List of Expansions
Table 12.2 Expansions: Information on Type of Cell
Table 12.3 Expansions: Information on Scale of Operation
Table 13.1 Big Pharma Players: List of Cell Therapy Manufacturing Initiatives
Table 14.1 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms: Average Capacity by Company Size (Sample Data Set for Industry Players)
Table 14.2 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area: Average Capacity by Company Size (Sample Data Set for Industry Players)
Table 14.3 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size
Table 14.4 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Company Size
Table 14.5 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms: Average Capacity for Non-Industry Players
Table 14.6 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area: Average Capacity for Non-Industry Players
Table 16.1 Costs Associated with the Manufacturing of Stem Cell Therapies
Table 16.2 Price of Marketed Gene / Cell Therapies
Table 16.3 Price of Marketed Target Drugs
Table 16.4 T-cell Immunotherapies: Expert Opinions on Pricing
Table 16.5 CAR-T Cell Therapies: Reimbursement Landscape
Table 18.1 Active Clinical Studies for Autologous Cell Therapies
Table 18.2 Active Clinical Studies for Allogeneic Cell Therapies
Table 18.3 Active Clinical Studies for Autologous Cell Therapies: Distribution by Patients Enrolled
Table 18.4 Active Clinical Studies for Allogeneic Cell Therapies: Distribution by Patients Enrolled
Table 22.1 Survey Insights: Overview of Respondents
Table 22.2 Survey Insights: Designations and Seniority Levels
Table 22.3 Survey Insights: Type of Cell Therapy
Table 22.4 Survey Insights: Scale of Operation
Table 22.5 Survey Insights: Source of Cells
Table 22.6 Survey Insights: Type of Cell Culture System Used
Table 22.7 Survey Insights: Availability of Fill / Finish Services
Table 23.1 Glycostem Therapeutics: Company Snapshot
Table 23.2 Bio Elpida: Company Snapshot
Table 23.3 Gracell Biotechnologies: Company Snapshot
Table 23.4 Kadimastem: Company Snapshot
Table 23.5 RoslinCT: Company Snapshot
Table 23.6 University of Minnesota: Organization Snapshot
Table 23.7 Lion TCR: Company Snapshot
Table 23.8 Center for Commercialization of Cancer Immunotherapy / C3i: Company Snapshot
Table 23.9 Waisman Biomanufacturing: Company Snapshot
Table 23.10 Yposkesi: Company Snapshot
Table 23.11 Cell Therapies: Company Snapshot
Table 23.12 CiMaas: Company Snapshot
Table 24.1 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size
Table 24.2 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment
Table 24.3 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Region-wise)
Table 24.4 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Country-wise)
Table 24.5 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Region-wise)
Table 24.6 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Country-wise)
Table 24.7 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Manufacturer
Table 24.8 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
Table 24.9 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Table 24.10 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Table 24.11 Cell Therapy Manufacturing (Industry Players): Distribution by Source of Cells
Table 24.12 Cell Therapy Manufacturing (Industry Players): Distribution by Scale of Operation
Table 24.13 Cell Therapy Manufacturing (Industry Players): Distribution by Manufacturing Capabilities / Services Offered
Table 24.14 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Region-wise)
Table 24.15 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Country-wise)
Table 24.16 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Region-wise)
Table 24.17 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Country-wise)
Table 24.18 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Manufacturer
Table 24.19 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Cell Manufactured
Table 24.20 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Immune Cell Manufactured
Table 24.21 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Stem Cell Manufactured
Table 24.22 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Source of Cells
Table 24.23 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Scale of Operation
Table 24.24 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Manufacturing Capabilities / Services Offered
Table 24.25 Cell Therapy Manufacturing (Industry Players): Distribution of Manufacturing Facilities by Regulatory Authorities
Table 24.26 Cell Therapy Manufacturing (Non-Industry Players): Distribution of Manufacturing Facilities by Regulatory Authorities
Table 24.27 Partnerships: Cumulative Year-wise Trend, 2016-2021 (Till February)
Table 24.28 Partnerships: Distribution by Type of Partnership
Table 24.29 Partnerships: Distribution by Year and Type of Partnership
Table 24.30 Partnerships: Distribution by Type of Cell
Table 24.31 Partnerships: Distribution by Type of Stem Cell
Table 24.32 Partnerships: Distribution by Type of T-Cell
Table 24.33 Partnerships: Distribution by Scale of Operation
Table 24.34 Partnerships: Distribution by Type of Cell and Scale of Operation
Table 24.35 Partnerships: Country-wise Distribution
Table 24.36 Partnerships: Continent-wise Distribution
Table 24.37 Most Active Players: Distribution by Number of Partnerships
Table 24.38 Acquisitions: Cumulative Year-wise Trend, 2016-2021 (Till February)
Table 24.39 Acquisitions: Year-wise Distribution by Type of Cell
Table 24.40 Acquisitions: Country-wise Distribution
Table 24.41 Acquisitions: Continent-wise Distribution
Table 24.42 Acquisitions: Ownership Change Matrix
Table 24.43 Expansions: Cumulative Year-wise Trend, 2016-2021 (Till February)
Table 24.44 Expansions: Distribution by Purpose of Expansion
Table 24.45 Expansions: Distribution by Type of Cell
Table 24.46 Expansions: Distribution by Purpose of Expansion and Type of Cell
Table 24.47 Expansions: Distribution by Scale of Operation
Table 24.48 Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
Table 24.49 Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
Table 24.50 Expansions: Distribution by Purpose of Expansion and Region
Table 24.51 Most Active Players: Distribution by Number of Expansions
Table 24.52 Most Active Players: Distribution by Area of Expansion
Table 24.53 Big Pharma Players: Distribution by Number of Cell Therapy Manufacturing Focused Initiatives
Table 24.54 Big Pharma Players: Cumulative Distribution by Year of Initiative
Table 24.55 Big Pharma Players: Distribution by Purpose of Initiative
Table 24.56 Big Pharma Players: Distribution by Type of Initiative
Table 24.57 Big Pharma Players: Distribution by Type of Partnership
Table 24.58 Big Pharma Players: Distribution by Type of Expansion
Table 24.59 Big Pharma Players: Distribution by Scale of Operation
Table 24.60 Big Pharma Players: Distribution by Types of Cells
Table 24.61 Big Pharma Players: Distribution by Purpose of Initiative and Company
Table 24.62 Big Pharma Players: Distribution by Year and Type of Initiative
Table 24.63 Big Pharma Players: Distribution by Region of Expansion and Company
Table 24.64 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size
Table 24.65 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation
Table 24.66 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Location of Manufacturing Facility
Table 24.67 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size and Location of Manufacturing Facility
Table 24.68 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 24.69 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Company Size
Table 24.70 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
Table 24.71 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Location of Manufacturing Facility
Table 24.72 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Company Size and Location of Manufacturing Facility
Table 24.73 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 24.74 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Scale of Operation
Table 24.75 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Location of Manufacturing Facility
Table 24.76 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Non-Industry Players): Distribution by Scale of Operation
Table 24.77 Installed Global Capacity for Cell Therapy Manufacturing, in Terms of Cleanroom Area (Non-Industry Players): Distribution by Location of Manufacturing Facility
Table 24.78 Global Demand for Cell Therapies, 2021-2030 (Number of Patients)
Table 24.79 Global Demand for Cell Therapies, 2021-2030 (Billion Cells)
Table 24.80 Global Clinical Demand for Cell Therapies, 2021-2030 (Number of Patients)
Table 24.81 Global Clinical Demand for Cell Therapies, 2021-2030: Distribution by Type of Cell Therapy (Number of Patients)
Table 24.82 Global Clinical Demand for Cell Therapies, 2021-2030: Distribution by Geographical Location (Number of Patients)
Table 24.83 Global Commercial Demand for Cell Therapies, 2021-2030 (Number of Patients)
Table 24.84 Global Commercial Demand for Cell Therapies, 2021-2030: Distribution by Type of Cell Therapy (Number of Patients)
Table 24.85 Global Commercial Demand for Cell Therapies, 2021-2030: Distribution by Geographical Location (Number of Patients)
Table 24.86 Global Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 24.87 Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Cell Therapy, 2021-2030 (USD Million)
Table 24.88 Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
Table 24.89 Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 24.90 Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Purpose of Manufacturing, 2021-2030 (USD Million)
Table 24.91 Cell Therapy Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
Table 24.92 Global Commercial Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 24.93 Commercial Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Type of Therapy, 2021-2030 (USD Million)
Table 24.94 Commercial Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
Table 24.95 Commercial Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
Table 24.96 Global Commercial Scale Manufacturing Market for NK Cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 24.97 Commercial Scale Manufacturing Market for NK Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
Table 24.98 Commercial Scale Manufacturing Market for NK Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
Table 24.99 Global Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 24.100 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Type of Therapy, 2021-2030 (USD Million)
Table 24.101 Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
Table 24.102 Global Commercial Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 24.103 Commercial Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
Table 24.104 Commercial Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
Table 24.105 Global Clinical Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 24.106 Clinical Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Type of Therapy, 2021-2030 (USD Million)
Table 24.107 Clinical Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
Table 24.108 Clinical Scale Manufacturing Market for T-cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
Table 24.109 Global Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 24.110 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Type of Therapy, 2021-2030 (USD Million)
Table 24.111 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
Table 24.112 Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
Table 24.113 Global Clinical Scale Manufacturing Market for NK Cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 24.114 Clinical Scale Manufacturing Market for NK Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
Table 24.115 Clinical Scale Manufacturing Market for NK Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
Table 24.116 Global Clinical Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 24.117 Clinical Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Source of Cells, 2021-2030 (USD Million)
Table 24.118 Clinical Scale Manufacturing Market for Stem Cell Therapies, Conservative, Base and Optimistic Scenarios: Distribution by Region, 2021-2030 (USD Million)
Table 24.119 Survey Insights: Distribution of Respondents by Type of Organization
Table 24.120 Survey Insights: Distribution of Respondents by Location of Manufacturing Facility
Table 24.121 Survey Insights: Distribution of Respondents by Designation and Seniority
Table 24.122 Survey Insights: Distribution by Type of Cell Therapy
Table 24.123 Survey Insights: Distribution by Scale of Operation
Table 24.124 Survey Insights: Distribution by Source of Cells
Table 24.125 Survey Insights: Distribution by Type of Cell Culture System Used
Table 24.126 Survey Insights: Distribution by Availability of Fill / Finish Services

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3P Biopharmaceuticals
  2. 3SBio
  3. A2 Biotherapeutics
  4. A2 Healthcare
  5. Abeona Therapeutics
  6. Accellta
  7. Achilles Therapeutics
  8. Adaptimmune
  9. Adva Biotechnology
  10. Advanced Cell Therapy Laboratory, Yale School of Medicine
  11. Advent Bioservices
  12. AGC Biologics
  13. Agenus (AgenTus Therapeutics)
  14. Akron Biotech
  15. Alberta Cell Therapy Manufacturing (ACTM)
  16. Allele Biotechnology and Pharmaceuticals
  17. Allogene Therapeutics
  18. Anterogen
  19. apceth Biopharma
  20. ArchiMed 
  21. Aspire Health Science
  22. Astellas Pharma
  23. Asterias Biotherapeutics
  24. Astero Bio (acquired by BioLife Solutions)
  25. Asymptote
  26. Atara Biotherapeutics
  27. Athersys
  28. Austrianova
  29. Autolus Therapeutics
  30. Bay City Capital 
  31. Bayer
  32. Bellicum Pharmaceuticals
  33. Bio Elpida
  34. BioCardia
  35. BioCentriq
  36. BioInno Bioscience
  37. Bioinova
  38. BioNTech IMFS
  39. Biopharmaceutical Development Program, National Cancer Institute
  40. BioRestorative Therapies
  41. BioTherapeutics Unit, Netherlands Cancer Institute
  42. bluebird bio
  43. BlueRock Therapeutics (acquired by Bayer)
  44. Bone Therapeutics
  45. Boyalife
  46. BrainStorm Cell Therapeutics
  47. Brammer Bio
  48. BriaCell Therapeutics 
  49. Bristol Myers Squibb
  50. C3i (Center of Excellence for Cellular Therapy)
  51. Caladrius Biosciences
  52. CancerRop
  53. Capricor Therapeutics
  54. CariCord (acquired by Celularity)
  55. CARsgen Therapeutics
  56. Catalent
  57. Catalent Biologics
  58. Catapult Therapy TCR (acquired by Cell Medica)
  59. Celgene
  60. Cell and Gene Therapy Catapult
  61. Cell and Gene Therapy Laboratory, Children’s Hospital of Philadelphia
  62. Cell Medica
  63. Cell Therapies
  64. Cell Therapies Core, Moffitt Cancer Center
  65. Cell Therapy and Regenerative Medicine, University of Utah
  66. Cell Therapy Manufacturing Facility, MedStar Georgetown University Hospital 
  67. Cell Therapy Suite, University of Birmingham
  68. Cell-Easy
  69. Cellectis
  70. Cellex Cell Professionals
  71. CELLforCURE
  72. Cellin Technologies
  73. CellMP (subsidiary of Emmecell)
  74. Cells for Sight Stem Cell Therapy Research Unit, University College London
  75. Cellular Biomedicine
  76. Cellular Therapy Core, Sidney Kimmel Comprehensive Cancer Center
  77. Cellular Therapy Core, University of Texas
  78. Cellular Therapy Integrated Services (CTIS), Case Western Reserve University
  79. Celonic
  80. Celularity
  81. Celyad
  82. Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
  83. Center for Cell and Gene Therapy, Baylor College of Medicine
  84. Center for International Blood and Marrow Transplant Research
  85. Centre for Biological Engineering, Loughborough University
  86. Centre for Cell and Gene Tissue Therapeutics, Royal Free Hospital London
  87. Centre for Cell and Vector Production (CCVP)
  88. Centre for Cell Manufacturing Ireland (CCMI), NUI Galway
  89. Centre for Stem Cell Research (CSCR), Christian Medical College
  90. Century Therapeutics
  91. Cesca Therapeutics
  92. CHA Biolab
  93. Chart Industries
  94. Children's GMP, St. Jude Children's Research Hospital
  95. China Regenerative Medicine International
  96. City of Hope
  97. Clean Cells
  98. Clinical Biomanufacturing Facility, University of Oxford
  99. Clinical Cell and Vaccine Production Facility (CVPF)
  100. CMIC
  101. CO.DON
  102. Cogent Biosciences
  103. Cognate BioServices
  104. CoImmune
  105. Comprehensive Cell Solutions (a division of New York Blood Center)
  106. Connell and O'Reilly Families Cell Manipulation Core Facility, Dana-Farber / Harvard     Cancer Center
  107. Cook MyoSite
  108. Creative Biolabs
  109. CRISPR Therapeutics
  110. Cryoport 
  111. CSIRO
  112. CTM CRC
  113. CureCell
  114. Cytopeutics
  115. CytoSen Therapeutics (Acquired by Kiadis Pharma)
  116. Daiichi Sankyo
  117. David and Etta Jonas Center for Cellular Therapy, UChicago Medicine
  118. DCPrime
  119. Dendreon
  120. ElevateBio
  121. Emory Cellular and Immunotherapy Core (formerly known as Emory Personalized     Immunotherapy Core)
  122. EUFETS
  123. ExCellThera 
  124. Fate Therapeutics 
  125. Formula Pharmaceuticals
  126. Fosun Pharma
  127. Fraunhofer Institute for Cell Therapy and Immunology
  128. Froceth
  129. FUJIFILM Cellular Dynamics
  130. Gamida Cell
  131. Gates Biomanufacturing Facility
  132. GC Cell (Previously known as Green Cross Cell)
  133. GE Healthcare Life Sciences
  134. GenCure 
  135. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  136. GenIbet Biopharmaceuticals
  137. Ghent University
  138. Gilead Sciences
  139. Glycostem Therapeutics
  140. Glycotope
  141. Gracell Biotechnologies
  142. Great Ormond Street Hospital, University College of London
  143. Green Cross LabCell
  144. GSK
  145. GX Acquisition
  146. Harvard University Stem Cell Institute 
  147. Health Sciences Authority
  148. Hebei Senlang Biotechnology
  149. Hemostemix
  150. Histocell
  151. Hitachi Chemical
  152. Holostem Terapie Avanzate
  153. Human Cellular Therapy Laboratory, Mayo Clinic
  154. Immuneel Therapeutics
  155. Immunomic Therapeutics
  156. Immunovative Therapies 
  157. IncoCell Tianjin (a wholly owned subsidiary of Boyalife)
  158. Indapta Therapeutics
  159. Innovative Cellular Therapeutics
  160. Instil Bio
  161. Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
  162. International Stem Cell Corporation
  163. Invetech
  164. Iovance Biotherapeutics
  165. IsoPlexis
  166. Ixaka (formerly known as Rexgenero)
  167. Janssen Pharmaceuticals
  168. Japan Tissue Engineering
  169. Jiuzhitang Maker Cell Technology
  170. John Goldman Centre for Cellular Therapy, Imperial College London
  171. Juno Therapeutics
  172. JW CreaGene
  173. JW Therapeutics
  174. Kadimastem
  175. Kangstem Biotech
  176. KBI Biopharma
  177. Kemwell Biopharma
  178. Kiadis Pharma 
  179. King's Clinical Research Facility
  180. Kite Pharma (acquired by Gilead Sciences)
  181. Krembil Cell Facility, St. Michael's Hospital
  182. KSQ Therapeutics
  183. Laboratory for Cell and Gene Medicine, University of Stanford
  184. Legend Biotech (A subsidiary of GenScript Biotech)
  185. Lineage Cell Therapeutics
  186. Lion TCR
  187. Longeveron
  188. Lonza
  189. Lyell Immunopharma
  190. Lykan Bioscience
  191. Lymphotec 
  192. Marker Therapeutics
  193. Massachusetts General Hospital
  194. MaSTherCell
  195. MaxiVAX
  196. MD Anderson Cancer Center
  197. Medeor Therapeutics 
  198. Medigene
  199. MEDINET
  200. MEDIPOST
  201. Merck
  202. Mesoblast
  203. Michael G. Harris Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering
  204. Midwest Stem Cell Therapy Center, University of Kansas Medical Center
  205. Miltenyi Biotec
  206. Minaris Regenerative Medicine
  207. Minovia Therapeutics
  208. Molecular and Cellular Therapeutics, University of Minnesota
  209. MolMed
  210. Mustang Bio
  211. National Eye Institute
  212. Ncardia
  213. Neon Therapeutics
  214. NeoProgen
  215. Netherlands Cancer Institute (NKI)
  216. New Jersey Innovation Institute (NJII)
  217. Newcastle Advanced Therapies
  218. NHS Blood and Transplant
  219. NIHR Guy's and St Thomas' Clinical Research Facility
  220. Nikon CeLL innovation
  221. Nipro
  222. Nkarta
  223. NKGen Biotech (formerly known as NKMax America)
  224. Nohla Therapeutics
  225. Noile-Immune Biotech
  226. Northwest Biotherapeutics
  227. Novadip Biosciences
  228. Novartis
  229. Novex Innovations
  230. Novo Nordisk
  231. Octane Biotech
  232. Ology Bioservices
  233. Ontario Institute for Regenerative Medicine
  234. Opexa Therapeutics
  235. Orca Bio
  236. OrganaBio
  237. Orgenesis
  238. Ori Biotech
  239. Overland Pharmaceuticals
  240. PersonGen BioTherapeutics
  241. Pfizer
  242. PharmaBio
  243. PharmaCell
  244. pHion Therapeutics
  245. Pluristem Therapeutics
  246. Precision BioSciences
  247. Promethera Biosciences
  248. Provia Laboratories
  249. Q-GEN Cell Therapeutics
  250. Rayne Cell Therapy Suite, King's College London
  251. Regenerative Medicine Center, Utrecht University
  252. Regeneus
  253. ReNeuron
  254. Research and Development Center for Cell Therapy, Foundation for Biomedical Research     and Innovation
  255. Riyadh Pharma
  256. Robertson Clinical and Translational Cell Therapy, Duke University
  257. RoosterBio
  258. Roslin Cell Therapies
  259. Rubius Therapeutics
  260. S.Biomedics
  261. Saint-Gobain
  262. SanBio
  263. Sangamo Therapeutics
  264. Scinogy
  265. SCM Lifescience
  266. Scottish National Blood Transfusion Service
  267. Seneca Biopharma
  268. Servier
  269. Sheba Medical Center
  270. Shibuya
  271. Sorrento Therapeutics
  272. SOTIO
  273. S-RACMO
  274. Stem Cell Institute
  275. Stemedica Cell Technologies
  276. Stemmatters 
  277. Stempeutics Research
  278. Sumitomo Dainippon Pharma
  279. Sydney Cell and Gene Therapy 
  280. Syngen Biotech
  281. Takara Bio
  282. Takeda Pharmaceutical
  283. TC BioPharm
  284. TCR2 Therapeutics
  285. Terumo BCT
  286. Tessa Therapeutics
  287. The Discovery Labs Center for Breakthrough Medicines
  288. The Ottawa Hospital Research Institute
  289. The Philip S. Orsino Facility for Cell Therapy, Princess Margaret Hospital
  290. TheraCell Advanced Biotechnology
  291. Therapeutic Cell Production Core, Seattle Children's Research Institute
  292. Therapeutic Cell Production Facility, Roswell Park Comprehensive Cancer Center
  293. Thermo Fisher Scientific
  294. ThermoGenesis
  295. TiGenix
  296. T-knife
  297. Tmunity Therapeutics
  298. TrakCel
  299. TreeFrog Therapeutics
  300. Triumvira Immunologics
  301. Trizell
  302. TVAX Biomedical
  303. TxCell
  304. UC Davis GMP Laboratory
  305. UCLA Human Gene and Cell Therapy
  306. Universal Cells
  307. University Hospital Basel
  308. University of North Carolina Lineberger Comprehensive Cancer Center 
  309. University of Wisconsin's Program for Advanced Cell Therapy
  310. UofR Cell Therapy Manufacturing Facility (UofR- CTMF)
  311. Vecura, Karolinska University Hospital
  312. Vericel
  313. VetStem Biopharma
  314. Vineti 
  315. Viscofan BioEngineering (A business unit of Viscofan)
  316. Waisman Biomanufacturing
  317. West Biotherapy
  318. WuXi AppTec
  319. Zelluna Immunotherapy

Segmentation

The USD 10+ billion (by 2030) financial opportunity within the cell therapy manufacturing market has been analyzed across the following segments:

  • Type of therapy
    • T-cell therapies (CAR-T therapies, TCR therapies, TIL therapies)
    • Dendritic cell therapies
    • Tumor cell therapies
    • Stem cell therapies
  • Source of cells
    • Autologous 
    • Allogeneic 
  • Scale of operation
    • Clinical 
    • Commercial 
  • Purpose of manufacturing
    • Contract manufacturing
    • In-house manufacturing
  • Key geographical regions 
    • North America
    • Europe
    • Asia Pacific
    • Rest of the world

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com